Bimagrumab Biosimilar - Research Grade

Human

ACVR2B

>1mg/ml

IgG1 - lambda2

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

Q13705

93

Blue ice

This research-grade biosimilar is an unconjugated, non-therapeutic analog of bimagrumab, a fully human monoclonal antibody built around the activin type II receptor system. It is manufactured for research use only and is not intended for clinical or diagnostic application. Bimagrumab was originally developed to counter muscle-wasting conditions by neutralising activin type II receptor signalling, thereby releasing skeletal muscle from the negative growth control imposed by myostatin, activins and GDF11. As a research reagent, this material reproduces the antigen-binding behaviour of the originator so investigators can study receptor blockade, ligand competition and downstream signalling in controlled in-vitro and functional settings. It is supplied as an unconjugated IgG1/lambda immunoglobulin at research-grade endotoxin levels, making it suitable for binding assays, neutralisation studies, and use as a reference or benchmarking control alongside other activin-pathway modulators. Because the reagent is offered in bulk quantities with defined isotype and purity, it supports reproducible experimental design across assay formats. It is positioned as a cost-effective, well-characterised alternative to the clinical originator for mechanistic and comparability research. Guidance provided here is for ichorbio to review. The nominal target, ACVR2B (activin receptor type IIB, ActRIIB; UniProt Q13705), is a single-pass transmembrane serine/threonine kinase receptor of the TGF-beta superfamily. It serves as a high-affinity receptor for myostatin (GDF8), activins and GDF11, which are negative regulators of skeletal muscle mass. Ligand binding recruits type I receptors and activates SMAD2/3 signalling, suppressing protein synthesis and myocyte growth. Notably, bimagrumab binds the activin type II receptors competitively with higher affinity than the natural ligands, and its activity reflects engagement of both ActRIIB and the closely related ActRIIA; concurrent neutralisation of both receptors is important for maximal effect on muscle. Blocking this axis relieves inhibition of muscle growth, driving increases in muscle mass and, in metabolic models, reductions in fat mass.

Activin receptor type IIB, ACTR-IIB, Activin receptor type-2B

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Bimagrumab (anti-ACVR2B) Biosimilar

Q: Is the Bimagrumab biosimilar available in gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities to support bulk and high-throughput preclinical experiments.

Q: Is this research-grade Bimagrumab biosimilar suitable for in vivo studies?

A: Yes, it is supplied in a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Bimagrumab biosimilar target?

A: It is an unconjugated, non-therapeutic research analog of Bimagrumab that binds ACVR2B; for research use only.